Reviva Pharmaceuticals (RVPH) News Today → Things Are Not Normal in America – Here’s What to Do (From Stansberry Research) (Ad) Free RVPH Stock Alerts $2.14 -0.68 (-24.11%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineReviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meetingglobenewswire.com - May 9 at 8:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHprnewswire.com - May 6 at 6:37 PMReviva Pharmaceuticals Holdings Inc Ordinary Shares RVPHmorningstar.com - May 4 at 11:01 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHprnewswire.com - April 28 at 9:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHstockhouse.com - April 28 at 5:05 AMRVPH: Full Year 2023 Resultsfinance.yahoo.com - April 25 at 3:15 PMRVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHbusinesswire.com - April 25 at 11:56 AMBrokers Set Expectations for Reviva Pharmaceuticals Holdings, Inc.'s Q1 2024 Earnings (NASDAQ:RVPH)marketbeat.com - April 24 at 5:58 AMHC Wainwright Weighs in on Reviva Pharmaceuticals Holdings, Inc.'s Q1 2025 Earnings (NASDAQ:RVPH)marketbeat.com - April 23 at 6:14 AMAnalysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)markets.businessinsider.com - April 22 at 10:58 AMReviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC Wainwrightmarketbeat.com - April 22 at 8:29 AMReviva Pharmaceuticals' (RVPH) "Speculative Buy" Rating Reiterated at Benchmarkmarketbeat.com - April 16 at 10:26 AMRVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER Datamsn.com - April 15 at 3:45 PMRVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023investorplace.com - April 15 at 2:03 PMReviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophreniafinanznachrichten.de - April 15 at 10:45 AMReviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business Highlightsfinanznachrichten.de - April 15 at 10:45 AMReviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophreniaglobenewswire.com - April 15 at 8:30 AMReviva Reports Full Year 2023 Financial Results and Recent Business Highlightsglobenewswire.com - April 15 at 8:05 AMReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Updatemarketbeat.com - April 14 at 12:38 AMReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meetingfinance.yahoo.com - March 28 at 8:09 AMReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meetingglobenewswire.com - March 28 at 8:00 AMReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meetingfinance.yahoo.com - March 27 at 1:47 AMOptimistic Buy Rating for Reviva Pharmaceuticals Based on Brilaroxazine’s Broad Therapeutic Promisemarkets.businessinsider.com - March 25 at 9:52 PMHC Wainwright Reaffirms "Buy" Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)marketbeat.com - March 25 at 8:21 AMReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Down 15.9% in Februarymarketbeat.com - March 15 at 1:24 PMRVPH Mar 2024 3.000 putfinance.yahoo.com - March 14 at 11:53 PMReviva to Present at the UBS Virtual CNS Dayglobenewswire.com - March 11 at 8:00 AMReviva to Present at the 36th Annual ROTH Conferenceglobenewswire.com - March 7 at 8:00 AMRVPH Mar 2024 3.500 callfinance.yahoo.com - March 3 at 2:35 PMRVPH Jan 2026 5.500 callfinance.yahoo.com - February 29 at 3:54 PMRVPH Apr 2024 12.500 callfinance.yahoo.com - February 27 at 3:14 PMRVPH Mar 2024 4.500 putca.finance.yahoo.com - February 23 at 2:58 PMReviva Pharmaceuticals Stock (NASDAQ:RVPH), Short Interest Reportbenzinga.com - February 22 at 7:37 PMReviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conferencefinance.yahoo.com - February 20 at 9:57 AMReviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conferenceglobenewswire.com - February 20 at 8:00 AMRVPH Mar 2024 3.000 callfinance.yahoo.com - February 17 at 12:43 AMRVPH Mar 2024 5.500 putfinance.yahoo.com - February 17 at 12:43 AMReviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conferencefinance.yahoo.com - January 25 at 9:53 AMRVPH Jan 2025 7.500 callca.finance.yahoo.com - January 17 at 1:31 AMReviva Pharmaceuticals: Reviva to Present at Webull LIVE! Healthcare Webinar on January 17finanznachrichten.de - January 10 at 8:20 AMReviva to Present at Webull LIVE! Healthcare Webinar on January 17finance.yahoo.com - January 10 at 8:20 AMReviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestonesfinance.yahoo.com - January 4 at 8:18 AMReviva Pharmaceuticals Stock (NASDAQ:RVPH) Dividends: History, Yield and Datesbenzinga.com - December 28 at 1:20 PMKaruna downgraded, Arm target raised: Wall Street's top analyst callsfinance.yahoo.com - December 26 at 1:07 PMAnalysts Offer Insights on Healthcare Companies: Alector (ALEC), Reviva Pharmaceuticals Holdings (RVPH) and Oculis Holding (OCS)markets.businessinsider.com - December 8 at 9:58 PMReviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conferencefinance.yahoo.com - November 30 at 7:25 PMReviva Pharmaceuticals Holdings (RVPH) Price Target Increased by 13.48% to 17.17msn.com - November 27 at 12:56 PMReviva Pharmaceuticals: Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinanznachrichten.de - November 21 at 6:48 PMReviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - November 20 at 7:15 PMRVPH: Raise & RECOVER Results Reviewfinance.yahoo.com - November 20 at 2:15 PM Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Proof that the Musk/Bezos rivalry is about to hit a new level (Ad)Elon Musk Humiliated Since Jeff Bezos and Elon Musk first met in 2004 — they've been involved in a bitter feud… from rockets, to electric vehicles to who's the world richest person…for going on two decades these two have been at each others throats… Go here now for full story. RVPH Media Mentions By Week RVPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVPH News Sentiment▼0.300.43▲Average Medical News Sentiment RVPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVPH Articles This Week▼31▲RVPH Articles Average Week Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACRS News ASRT News VTVT News CMRX News ONCY News GNLX News PRPH News MIST News HOOK News AFMD News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVPH) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
